New Delhi: India on Wednesday registered more than 2 million (20,37,870) recoveries of Covid-19 patients with highest-ever single day recovery of 60,091 people in the last 24 hours. With this India's COVID19 recovery rate went up to 73.64 per cent. India's testing, tracking and treatment strategy also helped the country in reducing the fatality rate to 1.91 per cent.
India's present active caseload (6,76,514) is less than 24.45 per cent. And, the difference between active and recovered cases now stands at 13,61,356.
The continuous efforts in the last few months to strengthen the country's health care system also yielded results. India at present has 1667 dedicated COVID hospitals, 3455 dedicated COVID health care centres and 11597 dedicated COVID health care centres with 15,45,206 isolation beds, 203959 oxygen supported beds and 53,040 ICU beds.
Significantly, India also recorded more than 8 lakh COVID tests for the second consecutive day on Wednesday.
With more than 8,01,518 tests conducted in the last 24 hours, India's total COVID tests now stand at 3,17,42,782. India also increased its number of testing per million population up to 23,002.
Meanwhile, three Pharma companies including Hetero labs, Cipla and Mylan have received a go-ahead from the subject expert committee to conduct the last stage clinical trial to determine its efficacy of Ramdesivir.
Officials said that country's apex drug regulator, DCGI will take a final call to give the go-ahead. It may be mentioned here that these three companies received Gilead Sciences approval to manufacture the drugs in May.
Meanwhile, 1,600 candidates will take part in the III phase of Oxford Covid19 vaccine trial to be conducted by the Serum Institute of India (SII) in 17 trial sites across India. The trial is likely to start in a day or two.
Read: SP Balasubrahmanyam's health condition continues to be critical: Hospital
